top of page

The Science: Complimentary Treatments

StiRx currently has a primary focus on development of long-acting gonococcal mAb (STX-426) and gonococcal vaccine (STX-428), with a chlamydia bsAb (STX-288) and other STI treatments in the exploratory phase of research.

science-graphics-30.png

Treatment as adjunctive therapy for repeat gonorrhea infections. For high-risk patients, potential use as long-acting immuno-prophylaxis.

science-graphics-17.png

Disease prevention in

all at-risk patient populations

bottom of page